Dr. Eduardo Urias, a radiation oncologist at the Covenant Health Cancer Institute, says Pluvicto is an IV medication that targets prostate cancer cells directly, delivering radiation in a short range to limit damage to healthy tissue. The trial is open to men needing help treating prostate cancer.
For men in Lubbock and the surrounding South Plains dealing with a prostate cancer diagnosis, this gives another option close to home instead of traveling out of the region for specialized care. Having a trial like this at the Joe Arrington Cancer Center keeps advanced treatment local, which matters for patients managing the stress of cancer care along with travel time and cost.
Specifics on eligibility and trial results were not detailed. Patients interested should talk with their care team at Covenant to see if they qualify.
Prostate cancer treatment in Lubbock now includes an IV option, a shift away from traditional radiation machines.